NEW YORK (GenomeWeb) – Interpace Diagnostics announced yesterday that the New York State Department of Health (NYSDOH) has approved its ThyraMir thyroid cancer classifier test.
ThyraMir analyzes the expression of 10 cancer-linked microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples. It is typically used in conjunction with Interpace's ThyGenX oncogene panel.
Although ThyraMir was launched in early 2015, additional licenses from the NYSDOH are required to offer such a test in New York. Interpace said that it also has filed for NY State approval of ThyGenX.
"We believe approval by New York State of ThyraMir is an indicator that our ThyGenX submission will be well received, and we subsequently look forward to launching the combination testing of ThyGenX and ThyraMir in the State of New York as soon as possible," Interpace President and CEO Jack Stover said in a statement.